A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
A phase 1/2, first-in-human, open-label study to evaluate the safety, tolerability, PK, and
efficacy of the novel ALK inhibitor TPX-0131 in pretreated subjects with ALK+ advanced or
metastatic non-small cell lung cancer (NSCLC). The study consists of two portions: 1) Phase 1
dose escalation, and 2) Phase 2 efficacy evaluation.